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============

The introduction of targeted therapies has unveiled a new era of personalized treatment in nonsmall cell lung cancer (NSCLC). Although the newer therapies have improved the survival in NSCLC patients, it still remains a leading cause of cancer-related deaths worldwide.\[[@ref1]\] The overall 5-year survival rate of 15% in NSCLC hints toward the need of a more accurate diagnosis of the disease at the molecular level so that it can be managed with appropriate strategies. It has been shown in various studies that majority of NSCLC patients harbor one or more activated pathways with mutations in various genes such as Kirsten RAS gene or epidermal growth factor receptor (EGFR) gene or the fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the intracellular domain of anaplastic lymphoma kinase (ALK), named as EML4-ALK.\[[@ref2][@ref3][@ref4][@ref5][@ref6][@ref7]\]

Various studies have reported the incidence of EGFR mutations in NSCLC in the range of 10% to 51.8% across different ethnicity.\[[@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15]\] Similarly, the incidence of ALK gene rearrangements in NSCLC has been reported in the range of 3%--13%.\[[@ref4][@ref5][@ref16][@ref17]\] While patients with activating mutations of EGFR gene show a better response to EGFR tyrosine kinase inhibitors (TKIs),\[[@ref2][@ref3]\] the tumors harboring ALK rearrangements respond better to crizotinib which is an oral ATP-competitive TKIs of ALK and c-MET.\[[@ref18]\] In a Phase 3 trial comparing crizotinib with chemotherapy in ALK-positive lung cancer patients, crizotinib has demonstrated an impressive response rate (PR) of 65% and progression-free survival (PFS) of 7.7 months as compared to 20% and 3 months in the chemotherapy group (*P* \< 0.001).\[[@ref19]\] Crizotinib therapy has also demonstrated a very high 1- and 2-year overall survival (OS) of 77% and 64%, respectively, in patients with advanced NSCLC.\[[@ref20]\]

The ALK Break Apart FISH Probe Kit became the first Food and Drug Administration (FDA)-approved companion diagnostic for targeted therapy with crizotinib in lung cancers. However, due to practical limitations of FISH technique, recent studies have investigated the immunohistochemistry (IHC) for ALK protein expression using an antibody D5F3 and signal amplification kit OptiView by Ventana Roche for high sensitivity and specificity as compared to FISH.\[[@ref21][@ref22][@ref23]\] The US FDA has approved Ventana anti-ALK (D5F3) CDx assay in June 2015 for the selection of ALK-rearranged lung adenocarcinoma patients eligible to receive crizotinib therapy. However, Indian data on efficacy of crizotinib in IHC-positive NSCLC patients are lacking. The present study was carried out to assess the efficacy and safety of twice daily crizotinib tablet (250 mg) in IHC-proven EML4-ALK fusion gene among Indian patients with adenocarcinoma lung in the routine clinical practice.

Subjects and Methods {#sec1-2}
====================

Patients with NSCLC, adenocarcinoma histology, whose tumors were found to be positive for EML4-ALK fusion gene using IHC, were considered for this study. Permission was obtained from the Ethics Committee before the start of the study. Clinical characteristics and treatment details were collected from the patient\'s medical records. ALK gene rearrangement was detected by IHC using a Ventana automated immunostainer (Ventana Medical Systems, Illkirch Graffenstaden, France). IHC was assayed on 4 μm neutral buffered formalin fixed; paraffin-embedded tumor tissues using a primary rabbit monoclonal ALK antibody (mAb) clone D5F3 obtained from Ventana USA. IHC staining was performed using a Ventana benchmark XT immunostainer. The slides were dried at 60°C for 1 h, deparaffinized using EZ Prep at 75°C for 4 min, and incubated with the primary mAb at a dilution of 1:50 for 1 h at 37°C. Detection was performed using a multimer technology system with the UltraView Universal DAB detection kit.

The primary endpoint of this study was PR. The width of the resultant confidence intervals (CIs) for parameters to be estimated was constructed with a significance level of 0.05, i.e., a 95% CI. OS and PFS were analyzed with the use of Kaplan--Meier survival analysis and estimates were provided with 95% CIs. Statistical analysis was performed using SAS 8.02 (SAS Institute Inc.).

Results {#sec1-3}
=======

A total of 25 NSCLC adenocarcinoma patients were included in the study. There were 14 (56%) women and 10 (44%) men with a median age of 53 years. Eleven (44%) patients were nonsmokers and Eastern Cooperative Oncology Group performance status of 1 and 2 was present in 18 (72%) and 7 (28%) patient, respectively. Baseline patient characteristics are presented in [Table 1](#T1){ref-type="table"}. All the patients were positive for EML4-ALK fusion gene and none of the patient was positive for EGFR mutations. All patients had Stage IV disease at the time of initiation of crizotinib therapy. One patient achieved complete response and twenty achieved PR for an overall PR of 84%. The median PFS was 11.8 months \[95% CI: 5.3--17.3 months; [Figure 1](#F1){ref-type="fig"}\]. The median OS was 20.6 months \[95% CI: 12.8--34.1 months; [Figure 2](#F2){ref-type="fig"}\]. Common toxicity criteria (CTC) Grade 1 and 2 adverse events were vomiting, anemia, cough, thrombocytopenia, hyponatremia, anorexia, and diarrhea that did not require any dose modification. Two (8%) patients experienced severe hepatotoxicity requiring discontinuation of crizotinib therapy \[[Table 2](#T2){ref-type="table"}\].
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Summary of patient demographic and tumor characteristics (*n*=25)
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Common toxicity criteria all grade toxicities
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Discussion {#sec1-4}
==========

The discovery of ALK was made more than 17 years ago as a fusion oncogene with nucleophosmin in a subset of anaplastic large cell lymphomas. The activity of ALK tyrosine kinase is significant for its oncogenicity. In NSCLC, ALK gene rearrangements were primarily reported in the year 2007.\[[@ref24]\] Studies on Caucasian and East Asian NSCLC population have reported the incidence of ALK gene rearrangements in the range of 3% to 13% using the FISH technique.\[[@ref4][@ref5][@ref16][@ref17]\] Studies on Indian ethnicity have reported the incidence of ALK gene rearrangement in NSCLC in the range of 2.7%--3% using the FISH technique.\[[@ref25][@ref26]\] Till date, there is only one published report from India on the incidence of ALK gene rearrangement in NSCLC using the IHC assay.\[[@ref27]\] The 13.5% incidence in this Indian study is several folds higher than the previous studies and indicates that a new ALK clone, 5A4, and D5F3 from Leica and cell signaling technology can accurately identify ALK gene rearrangement in NSCLC as compared to FISH.

The use of oral ATP, competitive TKI of ALK and c-MET, has shown a good PR of 65% in advanced NSCLC.\[[@ref19]\] Ever since its approval in the year 2011, crizotinib has become a personalized treatment option in NSCLC tumors harboring ALK rearrangements. A systematic review of nine studies including 729 patients revealed a 1-year OS of 77.1% and PFS of 9.17 months along with an improved objective PR with crizotinib therapy as compared to chemotherapy group.\[[@ref28]\]

The ALK Break Apart FISH Probe Kit (Abbott Molecular, Des Plaines, IL, USA) was the first FDA-approved companion diagnostic for targeted therapy with crizotinib in lung cancers. The reagent of this test comprised of a Spectrum Orange (red) labeled 250 kb probe to the 3' end of ALK along with Spectrum Green (green) labeled 300 kb probe to the 5' end of ALK. The signals for each probe are evaluated under a fluorescent microscope using an oil immersion objective. Two patterns of ALK rearrangement are observed, first the break-apart where the red and green signals gets splitted and the second where the green signal is lost and only isolated or single red signals (3' ALK) are observed.\[[@ref25]\]

Although the FISH technique is widely practiced, it has a limitation of a very high inter-reader variability along with false negatives and false positives.\[[@ref29]\] Furthermore, lack of technical expertise, requirement of specialized fluorescence microscopy equipment, and higher operational costs are other limitations of FISH technique in low-resource countries.

Due to practical limitations of FISH technique, IHC for ALK protein expression in NSCLC has been explored as a faster, economical, and less operator-dependent alternative. Data from recent studies have established that staining of sections on Ventana immunostainer (benchmark XT) using an antibody D5F3 and labeling as well as signal amplification kit OptiView by Ventana Roche have a high sensitivity and specificity as compared to FISH.\[[@ref21][@ref22][@ref23]\] The Ventana anti-ALK (D5F3) CDx assay has received the US FDA approval in June 2015 for the selection of ALK-rearranged lung adenocarcinoma patients. In a study by Ma *et al*., six ALK-positive lung adenocarcinoma patients who tested Ventana IHC positive and FISH negative showed a very high objective PR of 66.7% with crizotinib therapy.\[[@ref30]\] Similarly, in other studies comparing IHC using D5F3 antibody with FISH, the sensitivity and specificity of IHC has always exceeded 90%.\[[@ref21][@ref31][@ref32]\] Several studies have also advocated the screening of NSCLC patients for EML4-ALK gene fusions by IHC technique and applying FISH only in cases found positive by IHC.\[[@ref33][@ref34][@ref35]\] In addition to FISH and IHC, next-generation sequencing (NGS) is another diagnostic assay that has been explored for the detection of EML4-ALK gene fusions in lung adenocarcinoma patients.\[[@ref36]\] In a retrospective study of 51 consecutive patients with lung adenocarcinoma, four of the five cases that were IHC positive/FISH negative were found to be positive by the NGS assay, whereas a single case that was IHC negative/FISH positive was found to be negative for ALK rearrangement by NGS.\[[@ref23]\]

The overall PR of 84% in our study is higher to the previously published reports. Similarly, the median PFS of 11.8 months (95% CI: 5.3--17.3 months) and median OS of 20.6 months (95% CI: 12.8--34.1 months) in our study is also higher to the previously published reports. The higher PR, PFS, and OS achieved in our study demonstrate the high sensitivity and specificity of IHC as compared to FISH technique. Further, it establishes the clinical utility of IHC as a cost-effective alternative to FISH for the selection of ALK-rearranged lung adenocarcinoma patients that will benefit from crizotinib therapy. Crizotinib therapy was very well tolerated by our study population, and none of the patients required dose modifications. Two (8%) patients who experienced CTC Grade 4 hepatotoxicity were discontinued from the crizotinib therapy as per the clinical judgment of the treating physician.

Conclusions {#sec1-5}
===========

Our study reports the first Indian data on the clinical outcome of Crizotinib in IHC-proven EML4-ALK-rearranged lung adenocarcinoma patients. The encouraging PR, PFS, and OS achieved in our study population indicate that IHC can accurately identify EML4 ALK fusion gene mutations in lung adenocarcinoma patients who are responsive to ALK inhibitors such as Crizotinib. IHC should be considered as a cost-effective alternative to FISH for the detection of EML4-ALK gene fusions, especially in low-resource countries.
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